(Q24202283)

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

New clinical evidence from the European tobramycin trial in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Aerosol delivery of antibiotics to the lower airways of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

The long-term use of inhaled tobramycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Microbiological and immunologic considerations with aerosolized drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Administration of aerosolized antibiotics in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Defining a pulmonary exacerbation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Pulmonary exacerbations in cystic fibrosis and bronchiectasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Nebuliser devices for drug delivery in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Shifting patterns of inhaled antibiotic use in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Interpretative strategies for lung function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Inhaled antibiotics for long-term therapy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Update on treatment of pulmonary exacerbations in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Exacerbations in cystic fibrosis: 3--Management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008319.PUB2

7 January 2021